drug
(empagliflozin + metformin hydrochloride ER)
Marketedupdated 3mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6indications
investigational
Type 2 Diabetes
all catalysts(15)
approval · 15
Dec 9, 2016
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Dec 23, 2016
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Dec 13, 2017
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Oct 26, 2018
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Jan 24, 2020
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Jun 11, 2021
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Jun 11, 2021
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Mar 21, 2022
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Oct 13, 2022
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Feb 6, 2023
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Jun 20, 2023
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Jun 20, 2023
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Oct 30, 2023
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Mar 7, 2025
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Oct 24, 2025
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 20, 2026
126 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (96)
- Dec 11, 2034patentUS 9949998*PED
- Dec 11, 2034patentUS 9949998*PED
- Dec 11, 2034patentUS 9949998*PED
- Dec 11, 2034patentUS 9949998*PED
- Nov 17, 2034patentUS 9949997*PED
- Nov 17, 2034patentUS 9949997*PED
- Nov 17, 2034patentUS 9949997*PED
- Nov 17, 2034patentUS 9949997*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11813275*PED
- Oct 3, 2034patentUS 11813275*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 12433906*PED
- Oct 3, 2034patentUS 12433906*PED
- Oct 3, 2034patentUS 12433906*PED
- Oct 3, 2034patentUS 12433906*PED
- Jun 11, 2034method-of-use (U-2290)US 9949998
- Jun 11, 2034method-of-use (U-2290)US 9949998
- Jun 11, 2034method-of-use (U-2290)US 9949998
- Jun 11, 2034method-of-use (U-2290)US 9949998
- May 17, 2034method-of-use (U-3533)US 9949997
- May 17, 2034method-of-use (U-3533)US 9949997
- May 17, 2034method-of-use (U-3533)US 9949997
- May 17, 2034method-of-use (U-3533)US 9949997
- Apr 3, 2034method-of-use (U-2290)US 10258637
- Apr 3, 2034method-of-use (U-2290)US 10258637
- Apr 3, 2034method-of-use (U-2290)US 10258637
- Apr 3, 2034method-of-use (U-2290)US 10258637
- Apr 3, 2034method-of-use (U-3193)US 11090323
- Apr 3, 2034method-of-use (U-3193)US 11090323
- Apr 3, 2034method-of-use (U-3193)US 11090323
- Apr 3, 2034method-of-use (U-3193)US 11090323
- Apr 3, 2034method-of-use (U-4154)US 11666590
- Apr 3, 2034method-of-use (U-4154)US 11666590
- Apr 3, 2034method-of-use (U-4154)US 11666590
- Apr 3, 2034method-of-use (U-4154)US 11666590
- Apr 3, 2034method-of-use (U-3759)US 11813275
- Apr 3, 2034method-of-use (U-3759)US 11813275
- Apr 3, 2034method-of-use (U-3776)US 11833166
- Apr 3, 2034method-of-use (U-3776)US 11833166
- Apr 3, 2034method-of-use (U-3777)US 11833166
- Apr 3, 2034method-of-use (U-3776)US 11833166
- Apr 3, 2034method-of-use (U-4154)US 12263153
- Apr 3, 2034method-of-use (U-4154)US 12263153
- Apr 3, 2034method-of-use (U-4154)US 12263153
- Apr 3, 2034method-of-use (U-4154)US 12263153
- Apr 3, 2034method-of-use (U-4287)US 12427162
- Apr 3, 2034method-of-use (U-4287)US 12427162
- Apr 3, 2034method-of-use (U-4287)US 12427162
- Apr 3, 2034method-of-use (U-4287)US 12427162
- Apr 3, 2034method-of-use (U-4296)US 12433906
- Apr 3, 2034method-of-use (U-4294)US 12433906
- Apr 3, 2034method-of-use (U-4294)US 12433906
- Apr 3, 2034method-of-use (U-4296)US 12433906
- Sep 7, 2032patentUS 10596120*PED
- Sep 7, 2032patentUS 10596120*PED
- Sep 7, 2032patentUS 10596120*PED
- Sep 7, 2032patentUS 10596120*PED
- Mar 7, 2032formulationUS 10596120
- Mar 7, 2032formulationUS 10596120
- Mar 7, 2032formulationUS 10596120
- Mar 7, 2032formulationUS 10596120
- Aug 11, 2030patentUS 12115179*PED4.0y
- Aug 11, 2030patentUS 12115179*PED4.0y
- Aug 11, 2030patentUS 12115179*PED4.0y
- Aug 11, 2030patentUS 12115179*PED4.0y
- Feb 11, 2030method-of-use (U-4023)US 121151793.5y
- Feb 11, 2030method-of-use (U-4023)US 121151793.5y
- Feb 11, 2030method-of-use (U-4023)US 121151793.5y
- Feb 11, 2030method-of-use (U-4023)US 121151793.5y
- Feb 1, 2029patentUS 7579449*PED2.5y
- Feb 1, 2029patentUS 7579449*PED2.5y
- Feb 1, 2029patentUS 7579449*PED2.5y
- Feb 1, 2029patentUS 7579449*PED2.5y
- Aug 1, 2028compositionUS 75794492.0y
- Aug 1, 2028compositionUS 75794492.0y
- Aug 1, 2028compositionUS 75794492.0y
- Aug 1, 2028compositionUS 75794492.0y
- Oct 15, 2027patentUS 7713938*PED1.2y
- Oct 15, 2027patentUS 7713938*PED1.2y
- Oct 15, 2027patentUS 7713938*PED1.2y
- Oct 15, 2027patentUS 7713938*PED1.2y
- Apr 15, 2027compositionUS 7713938242d
- Apr 15, 2027compositionUS 7713938242d
- Apr 15, 2027compositionUS 7713938242d
- Apr 15, 2027compositionUS 7713938242d
FDA exclusivities (8)
- Dec 20, 2026PEDPediatric (6mo bonus)126d
- Dec 20, 2026PEDPediatric (6mo bonus)126d
- Dec 20, 2026PEDPediatric (6mo bonus)126d
- Dec 20, 2026PEDPediatric (6mo bonus)126d
- Jun 20, 2026M-296Method (3y)
- Jun 20, 2026M-296Method (3y)
- Jun 20, 2026M-296Method (3y)
- Jun 20, 2026M-296Method (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that